Effects of enrichment strategies on outcome of adrecizumab treatment in septic shock: Post-hoc analyses of the phase II adrenomedullin and outcome in septic shock 2 trial

PurposeAdrecizumab, a non-neutralizing antibody of adrenomedullin (ADM) was recently investigated regarding its potential to restore endothelial barrier function in septic shock patients with high plasma ADM levels. Circulating dipeptidyl peptidase 3 (cDPP3), a protease involved in the degradation o...

Descripció completa

Dades bibliogràfiques

Autors principals:	Dirk van Lier, Adrien Picod, Gernot Marx, Pierre-François Laterre, Oliver Hartmann, Claudia Knothe, Feriel Azibani, Joachim Struck, Karine Santos, Jens Zimmerman, Andreas Bergmann, Alexandre Mebazaa, Peter Pickkers
Format:	Artigo
Idioma:	Inglês
Publicat:	Frontiers Media S.A. 2022-12-01
Col·lecció:	Frontiers in Medicine
Matèries:	sepsis septic shock adrenomedullin dipeptidyl peptidase 3 AdrenOSS-2 Adrecizumab
Accés en línia:	https://www.frontiersin.org/articles/10.3389/fmed.2022.1058235/full
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!